All In Biotech

Drug Trial Radar · NCT00061542

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Nov 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 2003

Primary completion

Nov 2006

Study completion Nov 2006

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
May 30, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Male only, from 1 week, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of BETOPTIC S and Timolol Gel-forming solution in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • BETOPTIC S (betaxolol HCl)Drug

    betaxolol HC)

  • Timolol Gel-forming Solution (TGFS)Drug

    timolol maleate 0.25% and 0.5%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in IOPTime frame: Up to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alcon Call Center

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.